Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2‐deoxyglucose and etomoxir
- 1 May 2008
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 123 (2) , 476-483
Abstract
Inhibition of energy production as a strategy for potentiation of anticancer chemotherapy was investigated using 1 glycolysis inhibitor and 1 fatty acid β‐oxidation inhibitor—2‐deoxyglucose and etomoxir, respectively, both known to be clinically well tolerated. Eighteen anticancer drugs were screened for potentiation by these inhibitors. 2‐deoxyglucose potentiated acute apoptosis (24 hr) induced mainly by some, but not all, genotoxic drugs, whereas etomoxir had effect only on cisplatin. By contrast, etomoxir did potentiate the overall, 48 hr effects of some genotoxic drugs, and was in addition more efficient than deoxyglucose in potentiating the overall effects of several non‐genotoxic drugs. Both types of potentiation were largely lost in the absence of p53. Because cisplatin was potentiated by both energy inhibitors in both types of assay, it was investigated at additional concentrations and over longer time. Both energy inhibitors strongly potentiated non‐apoptotic concentrations of cisplatin in p53‐wildtype as well as in p53‐deficient, cisplatin‐resistant HCT116 colon carcinoma cells. Reduced ATP levels correlated with, but were not sole determinants, the antiproliferative effects. We conclude that the long‐term effects of cisplatin potentiation are important and either p53‐independent or improved by a lack of p53. We also conclude that although the potentiated drugs as yet have no obvious mechanistic factor in common, the strategy holds promise with genotoxic as well non‐genotoxic anticancer drugs.Keywords
Funding Information
- Swedish Cancer Society
- Cancerforeningen/King Gustaf V Jubilee Foundation
- Castegren Memorial Fund
- Ollie and Elof Ericsson Memorial Fund
- Socrates/Eurogendis Grant
This publication has 36 references indexed in Scilit:
- Lysosomes and Trivalent Arsenic Treatment in Acute Promyelocytic LeukemiaJNCI: Journal of the National Cancer Institute, 2007
- Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNAInternational Journal of Cancer, 2006
- Modification of myocardial substrate use as a therapy for heart failureNature Clinical Practice Cardiovascular Medicine, 2006
- Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cellsAmerican Journal of Physiology-Endocrinology and Metabolism, 2006
- Increased lipogenesis in cancer cells: new players, novel targetsCurrent Opinion in Clinical Nutrition and Metabolic Care, 2006
- Tricarboxylic acid cycle inhibition by Li+ in the human neuroblastoma SH-SY5Y cell line: A 13C NMR isotopomer analysisNeurochemistry International, 2005
- Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3Oncogene, 2004
- Characterization of a novel metabolic strategy used by drug‐resistant tumor cellsThe FASEB Journal, 2002
- Improving cancer radiotherapy with 2-deoxy-d-glucose: phase I/II clinical trials on human cerebral gliomasInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1996
- Increased expression of glycolysis‐associated genes in oncogene‐transformed and growth‐accelerated statesMolecular Carcinogenesis, 1989